The first trucks carrying a COVID-19 vaccine for widespread use in the United States are getting ready to roll out of a Michigan manufacturing plant
Shipments of the Pfizer vaccine will set in motion the biggest vaccination effort in American history at a critical juncture of the pandemic that has killed 1.6 million and sickened 71 million worldwide.
Federal officials say the first shipments of Pfizer’s vaccine will be staggered, arriving in 145 distribution centers Monday, with an additional 425 sites getting shipments Tuesday, and the remaining 66 on Wednesday. The vaccine, co-developed by German partner BioNTech, is being doled out based on each state’s adult population.
“It’s very exciting. I will be thrilled, that moment when we administer our first dose,” Snyder said Saturday. “That will clearly be a watershed moment for us.”
Snyder said the UPMC system estimates that half its employees are willing to get the vaccine as soon as it’s offered to them.
The vaccine is heading to hospitals and other sites that can store it at extremely low temperatures — about 94 degrees below zero. Pfizer is using containers with dry ice and GPS-enabled sensors to ensure each shipment stays colder than the weather in Antarctica.
Doses should be delivered to all vaccination sites identified by states, such as local pharmacies, within three weeks, federal officials said.
The 40-hospital Oschner Health System in Louisiana and Mississippi expects to receive more than 9,000 doses in the coming days, said Dr. Sandra Kemmerly, medical director of hospital quality.
Employees approved for the first round are getting texts and emails directing them to schedule their initial injection, she said.
“I would say there’s enthusiasm,” Kemmerly said Saturday. “There’s that thought that maybe they don’t have to be so afraid to come to work if they can be vaccinated and be immune.”
The rollout will ensure there is enough vaccine to give people the two doses needed for full protection against COVID-19. That means the government is holding back 3 million doses to give those vaccinated in the first round a second shot a few weeks later.
The Food and Drug Administration authorized emergency use of the vaccine Friday, saying it is highly protective and presents no major safety issues. While U.S. regulators worked for months to emphasize the rigor and independence of their review, they faced political pressure until the final stages.
While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not give it to those with a known history of severe allergic reactions to any of its ingredients.
Another vaccine by Moderna will be reviewed by an expert panel this week and soon afterward could be allowed for public use.
Perrone reported from Washington, Stobbe from New York and Scolforo from Harrisburg, Pennsylvania. Associated Press Medical Writer Lauran Neergaard in Alexandria, Virginia, and Health Writer Candice Choi in New York contributed to this story.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.